Table 3.

Chemotherapy regimens in second line

	Cisplatin group	Irinotecan group	Oxaliplatin group	Other group	P value
Number of patient	23 (28.8%)	22 (27.5%)	21 (26.3%)	14 (17.5%)	NS
Median number of cycle	5.0 (1.0-10.0)	5.0 (1.0-12.0)	4.0 (1.0-12.0)	2.0 (1.0-5.0)	NS
Median duration of treatment (mo)	2.7 (0.5-6.9)	3.2 (0.3-7.4)	2.3 (0.6-7.1)	2.3 (0.3-7.4)	NS
Disease control rate	10 (43.5%)	9 (40.9%)	9 (42.9%)	4 (28.6%)	NS
OS (mo)	6.7 (3.2-9.3)	4.5 (3.2-6.4)	4.5 (2.6-9.6)	5.2 (3.8-15.8)	NS
PFS (mo)	4.1 (1.9-6.7)	3.0 (2.0-6.1)	2.6 (1.8-5.4)	2.4 (2.1-10.1)	NS

OS: Overall survival; PFS: Progression-free survival; NS: Not significant.